Purpose The feasibility of sequencing circulating tumor DNA (ctDNA) in plasma as a biomarker to predict early relapse or poor prognosis in patients with follicular lymphoma (FL) receiving systemic immunochemotherapy is not clear.
Materials and Methods We sequenced DNA from cell-free plasma that was serially obtained from newly diagnosed FL patients undergoing systemic immunochemotherapy. The mutation profiles of ctDNA at the time of diagnosis and at response evaluation and relapse and/or progression were compared with clinical course and treatment outcomes.
Results Forty samples from patients receiving rituximab-containing immunochemotherapy were analyzed. Baseline sequencing detected mutations in all cases, with the major detected mutations being KMT2C (50%), CREBBP (45%), and KMT2D (45%). The concentration of ctDNA and tumor mutation burden showed a significant association with survival outcome. In particular, the presence of mutations in CREBBP and TP53 showed poor prognosis compared with patients without them. Longitudinal analysis of ctDNA using serially collected plasma samples showed an association between persistence or reappearance of ctDNA mutations and disease relapse or progression.
Conclusion Analysis of ctDNA mutations in plasma at diagnosis might help predict outcome of disease, while analysis during follow-up may help to monitor disease status of patients with advanced FL. However, the feasibility of ctDNA measurement must be improved in order for it to become an appropriate and clinically relevant test in FL patients.
Citations
Citations to this article as recorded by
Feasibility of Circulating Tumor DNA Detection in the Cerebrospinal Fluid of Patients With Central Nervous System Involvement in Large B-Cell Lymphoma Seok Jin Kim, Jin Ju Kim, Mi Ri Park, Bon Park, Kyung Ju Ryu, Sang Eun Yoon, Won Seog Kim, Saeam Shin, Seung-Tae Lee Annals of Laboratory Medicine.2025; 45(1): 90. CrossRef
Circulating tumor DNA in lymphoma: technologies and applications Lina Fu, Xuerong Zhou, Xiaoyu Zhang, Xuhua Li, Fan Zhang, Hongcang Gu, Xiaoxue Wang Journal of Hematology & Oncology.2025;[Epub] CrossRef
Molecular pathology of lymphoma and its treatment strategies: from mechanistic elucidation to precision medicine Zhongyu Wang, Shuai Feng, Xiangmei Yao, Renbin Zhao, Yujin Li, Maofeng Zheng, Zengzheng Li, Yajie Wang Frontiers in Immunology.2025;[Epub] CrossRef
Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment Alexis Claudel, Anne-Ségolène Cottereau, Emmanuel Bachy, Emmanuel Itti, Pierre Feugier, Cedric Rossi, Francois Lemonnier, Vincent Camus, Nicolas Daguindau, Guillaume Cartron, Emmanuelle Nicolas-Virelizier, Diana-Laure Mboumba, Christophe Cardoso, Côme Bom Blood.2025; 146(8): 913. CrossRef
Metabolic-immune axis in the tumor microenvironment: a new strategy for prognostic assessment and precision therapy in DLBCL and FL Chengqian Chen, Wei Guo, Haotian Wang, Luming Cao, Ou Bai Frontiers in Immunology.2025;[Epub] CrossRef
Genetic analysis of cell-free DNA in follicular lymphoma in comparison with tissue-derived DNA Yoshikazu Hori, Hiroki Hosoi, Mitsuo Osuga, Ryuta Iwamoto, Fumiyo Maekawa, Tadashi Okamura, Shogo Murata, Toshiki Mushino, Motomi Osato, Hitoshi Ohno, Nobuyuki Yamamoto, Shin-Ichi Murata, Yasuhiro Koh, Sonoki Takashi Leukemia & Lymphoma.2025; 66(14): 2633. CrossRef
Clinical applications of circulating tumor DNA in hematological malignancies: From past to the future Jun-Ying Li, Li-Ping Zuo, Jian Xu, Chun-Yan Sun Blood Reviews.2024; 68: 101237. CrossRef
Molecular Biomarkers in Prediction of High-Grade Transformation and Outcome in Patients with Follicular Lymphoma: A Comprehensive Systemic Review Marie Hairing Enemark, Jonas Klejs Hemmingsen, Maja Lund Jensen, Robert Kridel, Maja Ludvigsen International Journal of Molecular Sciences.2024; 25(20): 11179. CrossRef